Fellowship · Houston, TX
Sponsored by University of Texas M D Anderson Cancer Center
Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment.
Nature genetics · 2022 · 341 citations · Jason Schenkel
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 294 citations · Lucia Masarova
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.
Cancer cell · 2021 · 232 citations · Jason Schenkel
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Blood cancer discovery · 2023 · 119 citations · Lucia Masarova
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Leukemia · 2025 · 42 citations · Lucia Masarova
Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes.
Immunity · 2021 · 249 citations ·
The NCI-MATCH trial: lessons for precision oncology.
Nature medicine · 2023 · 142 citations · Mark Routbort
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
Haematologica · 2021 · 145 citations · Lucia Masarova